Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012925 | 0.85 | MAPK14 (0.48) | MAPK14MAPK13GAAMAPK12MAPK11 | |
| SCHEMBL4465670 | 0.83 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1781542 | 0.83 | GRN (0.57) | MAPK14MAPK13GAAMAPK12MAPK11 | |
| SCHEMBL1013221 | 0.82 | RAF1 (0.49) | MAPK14MAPK13GAAMAPK12MAPK11 | |
| SCHEMBL1010615 | 0.80 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1012412 | 0.80 | MAPK14 (0.60) | MAPK14MAPK13GAAMAPK12MAPK11 | |
| SCHEMBL1781943 | 0.78 | MAPK14 (0.70) | MAPK14MAPK13GAAMAPK12MAPK11 | |
| SCHEMBL25488154 | 0.78 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL19350918 | 0.78 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4459497 | 0.78 | MAPK14 (0.50) | MAPK14MAPK13GAAMAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885GAA 2713/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885GAA 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.